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Abstract
Background: We generated novel, effective candidate vaccine against Brucella abortus based on recombinant
influenza viruses expressing the Brucella ribosomal protein L7/L12 or outer membrane protein (Omp)-16 from the
NS1 open reading frame. The main purpose of this work was to evaluate the safety, immunogenicity and
protectiveness of vaccine candidate in laboratory animals.
Methods and Results: Four recombinant influenza A viral constructs of the subtypes Н5N1 or H1N1 expressing the
Brucella proteins L7/L12 or Omp16 were obtained by a reverse genetics method: Flu-NS1-124-L7/L12-H5N1,
Flu-NS1-124-Omp16-H5N1, Flu-NS1-124-L7/L12-H1N1 and Flu-NS1-124-Omp16-H1N1. Despite of substantial
modification of NS1 gene, all constructs replicated well and were retain their Brucella inserts over five passages in
embryonated chicken eggs (CE). Administration of the mono- or bivalent vaccine formulation via prime-boost
intranasal (i.n.), conjunctival (c.) or subcutaneous (s.c.) immunization was safe in mice; no deaths, body weight loss
or pathomorphological changes were observed over 56 days. Moreover, guinea pigs vaccinated i.n. with vaccine
vectors did not shed the vaccine viruses through their upper respiratory tract after the prime and booster
vaccination. These findings confirmed the replication-deficient phenotype of viral vectors. The highest antibody
response to Brucella antigen was obtained with constructs expressing L7/L12 (ELISA, GMT 242.5-735.0); whereas the
highest T-cell immune response- with construct expressing Omp16 (ELISPOT, 337 ± 52-651± 45 spots/4×10
5cells),
which was comparable (P > 0.05) to the response induced by the commercial vaccine B. abortus 19. Interestingly,
c. immunization appeared to be optimal for eliciting T-cell immune response. In guinea pigs, the highest protective
efficacy after challenge with B. abortus 544 was achieved with Omp16 expressing constructs in both monovalent or
bivalent vaccine formulations; protective efficacy was comparable to those induced by a commercial live B. abortus
19 vaccine.
Conclusion: Thus, influenza vectors expressing Brucella protective antigens can be developed as novel influenza
vectored vaccine against B. abortus infection.
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Brucella abortus is a facultative intracellular pathogen
capable of infecting and causing disease in both domes-
tic animals and humans [1]. At present, brucellosis
among cattle is prevented using live attenuated vaccines
from the strains B. abortus 19 or RB51. These vaccines
possess a high immunogenic effectiveness, but have a
number of serious disadvantages, primarily related to
their ability to induce abortion in pregnant cows, secre-
tion of the vaccine strain into the milk of vaccinated ani-
mals when they are used in adult cattle and the difficulty
of differentiating between vaccinated animals and in-
fected animals (only a concern for the B. abortus 19) [2].
Furthermore, both strains can cause systemic brucellosis
in humans [3].
Given that B. abortus is an intracellular pathogen, the
main criterion for new candidate vaccines is their ability
to elicit a cellular immune response in animals. It is well
recognized that the two key components of the protect-
ive reaction in infected animals are the formation of Th1
CD4
+ lymphocytes secreting interferon-gamma (IFN-γ),
a critical cytokine which is required to regulate the anti-
brucellosis activity of macrophages [4], and CD8
+ T lym-
phocytes that lyse Brucella-infected cells [5].
Attempts by various research groups to elicit effective
Th1 CD4
+ and CD8
+ T cell anti-brucellosis immune re-
sponses have resulted in the development of subunit (re-
combinant protein) vaccines [6-14] and DNA vaccines
[15-20], however in terms of protective efficacy, subunit
and DNA vaccines are still inferior to commercial live
attenuated vaccines.
An alternative strategy for the development of safe
and effective brucellosis vaccines is the use of live
genetically-modified vectors, i.e., non-pathogenic micro-
organisms (bacteria and viruses) that express a Brucella
antigen. To date, Escherichia coli [21], Salmonella enter-
ica [22], Ochrobactrum anthropi [23] and Semliki Forest
virus (SFV) [24] have been used as vectors for expressing
Brucella proteins in vivo. It has been shown that the
tested bacterial (intracellular) and viral vectors are
capable of infecting a wide range of cell types and
expressing Brucella antigens within the infected cells.
Furthermore, in all cases, Th1 CD4
+ and CD8
+ T-cell
anti-brucellosis immune responses were elicited in im-
munized animals [21-24].
In view of the positive results obtained using live viral
vectors and the practical advantages of the reverse genetics
method, which enables genetic manipulation of RNA-
containing viruses [25,26], we propose that recombinant in-
fluenza A viruses expressing the Brucella L7/L12 or
Omp16 proteins may potentially represent a novel candi-
date vector vaccine against brucellosis. According to
published data, L7/L12 ribosomal protein and Omp16
are immunodominant B. abortus proteins that elicit a
cellular immune response (Th1 and CD8
+ T cells)
[8-10,13,14,16,20,22]. The influ e n z aAv i r u sc o n t a i n sas e g -
mented genome consisting of eight negative-strand RNA
fragments. Of these, the smallest fragment (NS), encoding
two proteins: viral nonstructural protein (NS1) and nuclear
export protein (Nep), is convenient target for genetic ma-
nipulation since NS1 is able to tolerate foreign sequences
exceeding its own length [27]. Thus, the ORF of NS1 was
used for inserting Brucella s e q u e n c e si nt h i ss t u d y .T h eА/
Puerto Rico/8/34 (H1N1) strain was used as the backbone
for obtaining influenza A virus vectors expressing Brucella
L7/L12 or Omp16 sequences in a form of fusion proteins
with N- terminal 124 amino acid residues of NS1.
The mouse is the animal model most extensively used
to study chronic infection caused by Brucella spp. [28].
Therefore, there are several reports of experimental
work employing other laboratory animals are susceptible
to experimental infection with Brucella spp. Guinea pigs
are probably the most susceptible laboratory animal spe-
cies to Brucella infection. Guinea pigs inoculated sub-
cutaneously with infectious doses of B. abortus develop
a persistent bacteremia for 6 weeks after infection,
whereas the attenuated B. abortus S19 is cleared from
the blood at one week after infection [29]. Therefore, the
guinea pig model may be considered valuable for the
evaluation of candidate vaccine strains [11]. All classic
Brucella species were pathogenic for guinea pigs [28].
Accordingly, as the animal model for evaluating the pro-
tectiveness of our vaccine candidates we used guinea
pigs.
In this work, we demonstrate that our novel recom-
binant Influenza Viruses expressing the Brucella proteins
L7/L12 or Omp16, and combinations of thereof (bivalent
vaccine formulation) elicited a T-cell immune response
in mice after a prime-boost immunization regime via
various immunization routes, and also provided guinea
pigs with a high degree of protection against the virulent
strain B. abortus 544, which was comparable to that of-
fered by a commercial live vaccine produced from B.
abortus 19.
Results
Recombinant influenza A viruses expressing B. abortus
proteins L7/L12 or Omp16
Four recombinant influenza A viral constructs of the
subtypes Н5N1 or H1N1 expressing the Brucella pro-
teins L7/L12 or Omp16 were obtained by a reverse
genetics method: Flu-NS1-124-L7/L12-H5N1, Flu-NS1-124-
Omp16-H5N1, Flu-NS1-124-L7/L12-H1N1 and Flu-NS1-
124-Omp16-H1N1. All of the viral constructs replicated
well in embryonated chicken eggs (CE). It should be noted
that during the initial passages in CE, the viral constructs
had low infection and hemagglutination titers; however, as
the number of passages increased, the titers also increased
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viral constructs ranged from 7.95 ±0.22 to 9.2 ±0.14 Log10
EID50/ml. Examination of the NS1 gene by RT-PCR con-
firmed that all of the viral constructs retained their Brucella
inserts in CE over 5 passages (Figure 1A). The sizes of the
NS1 genes of the viral constructs containing Brucella pro-
teins L7/L12 or Omp16 corresponded to the size of that
amplified from the control pHW plasmids (1110 and
1242 bp, respectively). These results were confirmed by the
sequencing data, which showed that the nucleotide se-
quences of the NS1 gene of all of the viral constructs corre-
sponded to the Brucella proteins L7/L12 or Omp16 (data
not shown). Western blotting (Figure 1B) demonstrated
that the fusion proteins NS1-L7/L12 and NS1-Omp16, with
molecular masses of approximately 27 kDa and 33 kDa, re-
spectively, were correctly expressed in CE infected with the
viral constructs.
Safety in mice
The safety or degree of attenuation of the viral con-
structs was determined in mice using three routes of ad-
ministration, according to the methodology described in
the Methods section. No animals in any group died dur-
ing the entire observation period. The overall condition
of the animals in the experimental and control groups
was identical, in terms of physical activity, appetite and
outward appearance.
Analysis of weight changes in the mice over 28 days
after the prime or boost vaccinations showed an increase
in the animals’ body weight, regardless of the type of
viral construct or route of administration (data not
shown). Mice in the experimental groups showed a simi-
lar increase in body weight (about 3.9-4.8 g or 23.6-
29.0%) to the control group (4.7 g or 29.1%) by the end
of the observation period.
Morphological and histological examinations of mouse
organs (heart, lungs, liver, kidneys and spleen) 5 days
after the prime or boost vaccinations revealed an ab-
sence of macro- and microscopic pathological changes
(data not shown).
Evaluation of virus shedding from upper-respiratory tract
of the vaccinated guinea pigs
Titration results of nasal fluids in CE revealed that all
guinea pigs vaccinated with mono and bivalent vaccine
formulation by intranasal (i.n.) method did not shed the
vaccine viruses through the upper respiratory tract in an
observation period of 7 days after the prime and booster
vaccination (data not shown).
Antibody response against the Brucella L7/L12 and
Omp16 proteins in immunized mice
Blood samples were collected from mice of the experi-
mental and control groups 28 days after the prime (D
28) and boost (D 56) immunizations to detect antibodies
against L7/L12 and Omp16 using an enzyme-linked im-
munosorbent assay (ELISA). Single immunization with
the mono- and bivalent vaccine formulations Flu-NS1-
124-L7/L12-H5N1 and Flu-NS1-124-Omp16-H5N1 did
not elicit significant (P >0.05) Brucella antibody titers
(Figure 2). L7/L12 and Omp16-specific IgG, of 52.7 ±
10.7 and 40.0± 6.4, respectively were observed only in
one group of animals immunized by conjunctival (c.)
method with the bivalent vaccine formulation. In con-
trast to experimental mice, mice of the positive control
group vaccinated once with B. abortus 19 developed at
study day 28 a significant (P <0.0001) L7/L12-specific
IgG response (2048 ± 313), but no Omp16-specific IgG.
An increase in the geometric mean titer (GMT) of
antibodies against L7/L12 (9.3 –18.5-fold) and Omp16
(1.5-3.6-fold) for all tested routes of administration
was observed after the booster vaccination in the experi-
mental groups of mice immunized with the mono- and
bivalent vaccine formulations. However, the most signifi-
cant (Р <0.05-0.01) increase in the GMT of Brucella
antibodies after the booster vaccination was primarily
observed in the groups of c. immunized mice. A slight
decrease (P >0.24) of L7/L12-specifc IgG (1536±256)
was determined on day 56 in mice vaccinated once with
B. abortus 19 when compared with the data at day 28
after immunization. It should be noted that antibody ti-
ters against L7/L12 in animals from experimental and
positive control groups within the specified period of
vaccination had no significant (P >0.05) difference (ex-
cept for the group of mice vaccinated i.n. with monova-
lent viral construct Flu-NS1-124-L7/L12, P <0.01).
Evaluation of the T-cell immune response elicited by the
viral constructs
T h ed e g r e eo fBrucella-specific cellular immunity induced
in mice by the mono- and bivalent vaccine formulations ex-
pressing the L7/L12 or Omp16 proteins via different routes
Table 1 Infection and hemagglutination titers for the viral constructs during passage in chicken embryos (CE)
Passage level/
biological system
Infection (Log10 EID50/ml) /hemagglutination titer
Flu-NS1-124-L7/L12-H5N1 Flu-NS1-124-Omp16-H5N1 Flu-NS1-124-L7/L12-H1N1 Flu-NS1-124-Omp16-H1N1
1/CE 7.28±0.3/1:128 6.82±0.14/1:16 4.45± 0.14/1:128 4.2±0.08/1:4
3/CE 8.78±0.14/1:256 7.95± 0.14/1:256 7.95± 0.22/1:128 6.95± 0.14/1:256
5/CE 8.95±0.22/1:512 8.45± 0.08/1:512 9.2 ±0.14/1:512 7.95± 0.22/1:256
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mined using an enzyme-linked immunospot assay (ELI-
SPOT) assay 28 days after the boost vaccination. Compared
to the control group (PBS), the mono- and bivalent vaccine
formulations administered by prime-boost vaccination
elicited a strong T-cell immune response (Р<0 . 00 5 or
Р< 0.001), regardless of the route of administration, as indi-
c a t e db yt h ep r e s e n c eo fal a r g en u m b e ro fI F N - γ-
producing lymphocytes (ranging from 112 ±9 to 651±45
spots/4 × 10
5 cells; Figure 3). Compared to the group of an-
imals vaccinated with the Flu-NS1-124-L7/L12 (Н5N1 +
H1N1) viral constructs, the number of spots were signifi-
cantly higher for the groups of mice vaccinated with the
viral vectors encoding the Brucella Omp16 protein, espe-
cially when administered by the c. (Р<0 . 00 5orР<0.0001)
and subcutaneous (s.c.; Р<0 . 0 5orР< 0.025) routes. There
was no significant difference (Р>0.05) in the number of
spots for the individual viral constructs expressing the L7/
Figure 1 Genetic stability of the viral constructs after five passages in chicken embryos (CE), as determined by RT-PCR (A) and
confirmation of expression of the Brucella proteins L7/L12 or Omp16 by the viral constructs using Western blotting (B). Figure 1A: 1)
Flu-NS1-124-Omp16-H5N1; 2) pHW plasmid encoding the NS1-124-Omp16 genes; 3) Flu-NS1-124-Omp16-H1N1; 4) Plasmid NS1-124-Omp16; 5)
Flu-NS1-124-L7/L12-H5N1; 6) Plasmid NS1-124- L7/L12; 7) Flu-NS1-124-L7/L12-H1N1; 8) Plasmid NS1-124- L7/L12. Figure 1В: 1) lysed allantoic fluid
(AF) of uninfected CE; 2) lysed AF of CE infected with Flu-NS1-124-Omp16-H5N1; 3) lysed AF of CE infected with Flu-NS1-124-Omp16-H1N1; 4)
lysed AF of uninfected CE; 5) lysed AF of CE infected with Flu-NS1-124- L7/L12-H5N1; 6) lysed AF of CE infected with Flu-NS1-124- L7/L12-H5N1.
Figure 2 Titers of antibodies against the L7/L12 and Omp16 proteins in mice from the experimental and control (on 28 [A] and 56 [B]
days after a single vaccination with B. abortus 19 or administration of PBS) groups 28 days after prime (A) and boost (B) immunization
by different routes of administration with mono- or bivalent vaccine formulations of the subtypes Н5N1 and Н1N1, as determined by
ELISA. Data for the control group is not shown; i.n. – intranasally, c. – conjunctivally, s.c. – subcutaneously; Ag – antigen. The data are presented
as geometric mean titer (GMT)± standard error (SE); * P<0.05, † P< 0.01 compared to single vaccination (n= 5 mice per group). Statistical
analysis was performed using a one way ANOVA followed by Tukey’s multiple comparisons test.
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administration. Among all of the experimental groups of
mice only two groups which were immunized by c. route
with viral vectors encoding the Brucella Omp16 protein in-
duced comparable number of spots (P >0.05) than did mice
of the positive control group vaccinated with B. abortus 19.
Spot numbers in remaining experimental groups were sig-
nificantly lower (Р<0 .0 1-Р<0.0001).
Study of protective efficacy
The protective efficacy of the mono- and bivalent vac-
cine formulations was investigated in a guinea pig model
and compared to a commercial live vaccine produced
from strain B. abortus 19, according to the methodology
described in the Methods section. The protective efficacy
of the vaccines was evaluated using parameters such as
the effectiveness of vaccination, index of infection (I.I.
is the number of organs and lymph nodes from which
Brucella bacteria were isolated), and bacterial load of the
virulent B. abortus challenge strain 544 in spleens of
vaccinated and unvaccinated (PBS) animals.
Compared to the control (PBS) group, all of the vaccines,
regardless of the route of administration, provided signifi-
cant protection (Р<0 .0 1 - Р< 0.001) of the guinea pigs
against infection by the strain B. abortus 544 to some ex-
tent, in terms of bacterial load of the virulent strain in
spleens of animals after challenge (Table 2). According to
the I.I. (Figure 4) significant protection compared to the
control (PBS) group was achieved only in the animals that
were c. vaccinated with monovalent viral constructs ex-
pressing the Omp16 protein (P< 0.005; effectiveness of vac-
cination 60%) and bivalent vaccine formulation expressing
the L7/L12 and Omp16 proteins (P < 0.001;e f f e c t i v e n e s so f
vaccination 60%), and also in the animals vaccinated with
B. abortus 19 (P <0.0006; effectiveness of vaccination 60%).
It should be emphasized that the I.I. in animal groups vac-
cinated with the above-mentioned viral constructs were
similar (Р>0.99) to those vaccinated with the commercial
B. abortus 19 vaccine.
Discussion
The currently available commercial live Brucella vaccines
have serious intrinsic drawbacks, which is why vaccination
is restricted in many countries prone to brucellosis. This
situation has motivated many researchers to develop new
generations of vaccines which do not possess such draw-
backs, but which can induce the same protection efficacy as
commercial vaccines.
In our opinion, of the strategies currently being proposed,
live vector vaccines are the most likely replacement for
existing commercial vaccines against bovine brucellosis,
given the long-term experience of their successful use in
veterinary practice [30].
In this study, we first developed recombinant influenza
A viruses of the subtypes Н5N1 and H1N1 expressing
Brucella ribosomal protein L7/L12 or Omp16, and then
demonstrated that these vaccines could be used as new
candidates for a brucellosis vaccine. The choice of the
Brucella proteins L7/L12 and Omp16 as antigenic
determinants was based on their immunodominance in
eliciting Th1 CD4
+ and CD8
+ T-cell immune responses
[8-10,13,14,16,20,22]. In addition, it was previously
shown that these recombinant proteins, both when pure,
combined with adjuvants, or expressed by DNA vac-
cines, provided mice with good protection when chal-
lenged with virulent B. abortus 544 [8,10,13,14,20].
A large body of data [31-34] has confirmed the ability
of influenza viruses to infect cattle and elicit a sero-
logical reaction and, in some cases clinical disease, which
provided the basis for choosing influenza A viruses as
the vaccine vector in this study. Thus, the attenuated in-
fluenza A viruses selected as the vector should be able
to infect cattle and express the recombinant Brucella
proteins. The potential of the influenza A NS vector was
Figure 3 Quantitative ELISPOT analysis of IFN-γ-producing
lymphocytes in immunized mice after in vitro stimulation of
isolated splenocytes (4 x 10
5cells) with the Brucella proteins L7/
L12 or Omp16 or heat-inactivated B. abortus 19 (10
6CFU). The
mice were immunized with mono- and bivalent vaccine formulations
of the subtypes Н5N1 or H1N1 by prime-boost intranasal (i.n.),
conjunctival (c.) or subcutaneous (s.c.) vaccination 28 days apart, and
with B. abortus 19 by single s.c. vaccination. Mice from the negative
control groups were s.c. administered with PBS. Quantitative spot±SE
values (3 replicates per mouse) are presented for each group of 5 mice.
*Р<0. 00 5orР<0.0001 compared to the all group of animals
vaccinated with the Flu-NS1-124-L7/L12 (Н5N1+H1N1) viral constructs;
**Р<0. 05orР<0.025 compared with º; ***Р<0. 05orР<0 .0 2 5
compared with †. Statistical analysis was performed using a one way
ANOVA followed by Tukey’s multiple comparisons test.
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a tuberculosis vaccine [35].
On the basis of previous study [36], and in order to
achieve maximum expression of the Brucella proteins
in vivo and elicit an increased T-cell immune response, the
laboratory animals were immunized using a double vaccin-
ation schedule with viral constructs of the Н5N1 subtype
(prime vaccination) and H1N1 subtype (booster vaccin-
ation). This immunization strategy effectively overcomes
the immune background elicited against the viral vector
during primary vaccination.
Since influenza viruses are primarily transmitted
within droplets, and reproduce in the mucous mem-
branes of the respiratory tract, the i.n. route was chosen
for immunizing the animals, and the c. and s.c. routes
were used for comparison. The mucosal routes of ad-
ministration (i.n. and c.) were chosen as the mucous
membranes are the main gateway for brucellosis infec-
tion, and these routes have been shown to provide im-
munized animals with a high level of protection against
the virulent B. abortus strain [13,37].
The first series of experiments established that des-
pite the truncated nature of the NS1 gene, the viral
constructs Flu-NS1-124-L7/L12-H5N1, Flu-NS1-124-Omp
16-H5N1, Flu-NS1-124-L7/L12-H1N1, and Flu-NS1-124-
Omp16-H1N1 had good reproductive properties in CE
over five consecutive passages and retained their Brucella
inserts.
Table 2 Degree of protective efficacy of the vaccines as evaluated by the isolation rate of Brucella from the spleens of
guinea pigs challenged with the virulent strain B. abortus 544
Vaccine Route of
administration
Log10 CFU/spleen
(mean±SE)
Log10
protection
*Value (P)
Monovalent Flu-NS1-124-Omp 16 (H5+H1) i.n. 2.0±0.52 2.54 <0.01
c. 0.76±0.44 3.78 <0.001
s.c. 1.26±0.52 3.28 <0.005
Monovalent Flu-NS1-124-L7L12 (H5+H1) i.n. 1.22±0.50 3.32 <0.001
c. 2.4±0.25 2.14 <0.005
s.c. 1.46±0.39 3.08 <0.001
Bivalent vaccine formulation Flu-NS1-124-Omp 16+ Flu-NS1-124-L7L12 (H5+H1) i.n. 1.28±0.52 3.26 <0.005
c. 0.64±0.40 3.90 <0.001
s.c. 1.68±0.51 2.86 <0.005
B. abortus 19 s.c. 0.42±0.26 4.12 <0.001
Control (PBS) s.c. 4.54±0.43 0.00
i.n. – intranasally, c. – conjunctivally, s.c. – subcutaneously; *compared with control group. Statistical analysis was performed using a one way ANOVA followed by
Tukey’s multiple comparisons test.
Figure 4 Protective efficacy of the vaccines in a guinea pig model when administered by different routes, as evaluated by index of
infection (A; the number of organs and lymph nodes from which Brucella was isolated) and effectiveness of vaccination (B). The guinea
pig were immunized with mono- and bivalent vaccine formulations of the subtypes Н5N1 or H1N1 by prime-boost intranasal (i.n.), conjunctival
(c.) or subcutaneous (s.c.) vaccination 28 days apart, and with B. abortus 19 by single s.c. vaccination. Guinea pigs of the negative control groups
were obtained s.c. of PBS. * P<0.005,* *P<0.001, *** P< 0.0006 compared to negative control groups. Statistical analysis was performed using a
one way ANOVA followed by Tukey’s multiple comparisons test.
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of the NS1 gene decreased in viral vectors, the degree of
attenuation of the influenza A viruses increased [38];
however, it is well known that attenuation of influenza
viruses may be dependent on the properties of the for-
eign insert in the C-terminal part of the truncated NS1
protein [39]. Therefore, we considered it necessary to
study the safety or degree of attenuation of the con-
structed recombinant influenza A viruses in mice, which
provide the most sensitive model for testing the safety of
influenza vectors. Both the mono- and bivalent vaccine
formulations containing Brucella inserts (L7/L12 or
Omp16) in the NS1 gene were safe in mice when admin-
istered by the i.n., c. or s.c. routes. No deaths, loss of
body weight or pathomorphological changes occurred in
the mice over the entire observation period, which pro-
vided evidence for the attenuation of the influenza A
viruses.
Moreover it has to be noted that all guinea pigs vacci-
nated with mono and bivalent vaccine formulation by
i.n. method did not shed the vaccine viruses through
their upper respiratory tract the entire week after the
prime and booster vaccination. These results proved the
replication-deficient properties of the virus vectors and
confirm no danger of viral transmission from vaccinated
to non-vaccinated animals or people. Interestingly, one
vaccine vector is based on the prepandemic flu A/H5N1
delNS1 vaccine. It was shown previously that this vac-
cine is completely safe and immunogenic when tested in
a variety of laboratory models (chickens, ferrets and rhe-
sus macaques) [40] and humans [41]. We can assume
that this vaccine in the future can be used not only for
cattle but also for humans.
Furthermore, the mono- and bivalent vaccine formula-
tions of the subtypes Н5N1 and H1N1 elicited antigen-
specific humoral and T-cell immune responses after
prime-boost immunization via all of the tested routes of
administration. The greatest antibody response (by
ELISA) was obtained with the viral constructs expressing
the Brucella protein L7/L12; and the greatest T-cell im-
mune response by ELISPOT assay was obtained with
viral constructs expressing the Omp16 protein (c.
immunization), not inferior (P>0.05) to commercial
vaccine B. abortus 19. It should be noted that, as the
humoral and cellular immune responses indicate, the
bivalent vaccine formulation were in no way inferior
(P >0.05) to their monovalent variants, despite the lower
(by half) dose injected; the bivalent vaccine formulation
even somewhat surpassed their monovalent variants. We
also demonstrated that single or combined injection of
mice with viral constructs expressing two different
Brucella proteins did not lead to interference between
the constructs, as the mice immunized with bivalent
vaccine formulation formed a humoral and cellular
immune responses to both (L7/L12 or Omp16) protein
of B. abortus. The optimal T-cell immune responses
were achieved by the c. immunization route, despite the
fact that influenza viruses primarily reproduce in re-
spiratory tract organs. In our opinion, this is mainly due
to the ability of influenza viruses to reproduce not only
in the conjunctival mucous membrane, but also in the
cells of the cornea thus priming the conjunctiva-
associated lymphoid tissue (CALT) and eye-associated
lymphoid tissue (EALT). CALT can detect antigens from
the ocular surface, present the antigens and generate
protective effector cells; together, these properties signify
the presence of a mucosal immune system at the con-
junctiva [42-44]. Theoretically, the administration of an-
tigens into the conjunctival sac would additionally drain
to the nasal-associated lymphoid tissue (NALT). It was
shown previously that conjunctival or intraocular infec-
tion with influenza viruses stimulates the local as well as
systemic immune response [45]. Another explanation for
the higher cellular immunity obtained using viral con-
structs expressing Omp16 is that it Omp16 is able to act
as an adjuvant and activate dendritic cells and macro-
phages in vitro, according to Pasquevich et al. [46].
Data in mice have found a logical reflection in experi-
ments with guinea pigs. Guinea pigs were chosen as
model animals for studying the protective efficacy of the
viral constructs in this study due to their higher resist-
ance to influenza infection than mice [35]. In this case,
the use of a more resistant animal model was a key con-
dition for studying protective efficacy, since the vaccine
is ultimately intended for cattle. Furthermore, according
to Silva et al., guinea pigs are the most susceptible model
for evaluating protective efficacy [28] for the commercial
live brucellosis vaccine produced from strain B. abortus
19, This strain was used as a reference in the present
study. The protective efficacy of the vaccines was evalu-
ated by assessing both the bacterial load of the virulent
strain B. abortus 544 in spleens of vaccinated and unvac-
cinated animals, and by other parameters such as the ef-
fectiveness of vaccination and I.I. In our opinion, when
taken together, these parameters provide a more
complete and objective characterization of the protective
efficacy of vaccines.
In this study, guinea pigs were challenged with B.
abortus 544 at a dose of 5 × 10 CFU/animal, while in
other similar studies, mice were used as the model ani-
mals and higher doses of 4 × 10
4 -5×1 0
5 CFU were ad-
ministered [6,13,20]. Our previous studies (unpublished
data) showed that s.c. administration of five B. abortus
544 microbial cells caused generalized infection (mini-
mum infective dose) in guinea pigs. On this basis, a dose
of ten times the minimum infective dose, i.e., 5 ×
10 CFU/animal, was used to evaluate the protective effi-
cacy of the vaccines. This dose enabled a more objective
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vaccines.
In terms of the effectiveness of vaccination, I.I., and isola-
tion rate, the highest levels of protection were achieved in
t h eg u i n e ap i g sw h i c hw e r ec. vaccinated with monovalent
viral constructs expressing the Omp16 protein and bivalent
vaccine formulation expressing the L7/L12 and Omp16
proteins. It is noteworthy that the groups revealing the
highest protective efficacy also induced also the best cell-
mediated immunity. These experiments demonstrated that
the monovalent viral constructs expressing the Omp16 pro-
tein and bivalent vaccine formulation expressing the L7/
L 1 2a n dO m p 1 6p r o t e i n s ,w h en administered in prime-
boost c. immunization mode, were comparable in terms
vaccine effectiveness and protective efficacy to the commer-
cial live vaccine produced from strain B. abortus 19 in
guinea pigs. It should be noted that the results obtained in
the present study was successfully used in evaluating the
immunogenicity and efficacy of our vector vaccine in cattle.
It has been established that the administration of the vector
vaccine via the c. method of vaccination promoted forma-
tion of IgG antibodies (with a predominance of antibodies
of isotype IgG2a) in cattle against Brucella L7/L12 and
Omp16 proteins in ELISA. Moreover, these vaccines in cat-
tle induced a strong antigen-specific T-cell immune re-
sponse and provided a high level of protection efficacy
comparable to those of the commercial B. abortus S19 vac-
cine [47].
Conclusions
Thus, we conclude that administration of recombinant
influenza A viruses of the Н5N1 and H1N1 subtypes ex-
pressing L7/L12 or Omp16 in prime-boost i.n., c. or s.c.
immunization modes is safe; induce antigen-specific
humoral and T-cell immune responses in laboratory ani-
mals, and, most importantly, provide a high degree of
protective efficacy which is comparable to that offered
by a commercial live vaccine produced from strain B.
abortus 19. On this basis, we propose that this recom-
binant influenza A viruses represent a novel, effective
candidate vaccine against B. abortus.
Methods
Cells
The Vero (kidney epithelial cells isolated from an African
green monkey) and MDCK (Madin-Darby Canine Kidney)
cell lines originated from the American Type Culture Col-
lection (Manassas, VA, USA). Vero adapted to grow in
serum-free medium were maintained in a serum-free
OPTIPRO medium (GIBCO). MDCK cells were cultivated
in a 1:1 mixture of DMEM and Ham’sF 1 2m e d i u mc o n -
taining 2% heat inactivated fetal bovine serum (FBS;
SH30071; HyClone, Logan, UT, USA) and 4 mM L-
glutamine.
Bacterial strains
The vaccine strain B. abortus 19 (Shchelkovsky Biokom-
binat, Moscow oblast, Russia) and the virulent strain B.
abortus 544 (obtained from our institute’s collection of
microorganisms) were used in this study. The bacterial
cells were cultured under aerobic conditions in tryptone
soy agar (TSA; Sigma, St. Louis, MO, USA) at 37°C. All
experiments with live Brucella were performed in bio-
safety level 3 facilities. Escherichia coli strain T7 (New
England Biolabs, Frankfurt am Main, Deutschland, UK)
was used to prepare the recombinant proteins. The E.
coli cultures were routinely grown at 37°C in Luria-
Bertani (LB) broth or agar which was supplemented,
when required, with 100 μg/ml ampicillin.
Generation of viruses
All viruses were generated by a standard reverse genetics
method using 8 bidirectional plasmids pHW2000 [48].
Briefly, Vero cells were co-transfected by LonzaNucleo-
fector™ (Cologne, Germany) technique with 0.5 μg/μlo f
plasmids encoding the PB1, PB2, PA, NP, M gens and
NS (chimeric) gene of А/Puerto Rico/8/34 (H1N1) virus;
and the HA and NA genes of A/chicken/Astana/6/05
(H5N1) or А/New Caledonia/20/99 (H1N1) strains. The
HA protein sequence of the H5 virus was attenuated by
means of exchanging its polybasic cleavage site to one
containing a trypsin-dependent sequence. The NS genes
were modified to express NS1 fusion proteins containing
a sequence of 124 N-terminal amino acids from the NS1
protein coupled with a sequences of B. abortus derived
proteins: L7/L12 (GenBank: AAA19863.1) or Omp16
(GenBank: AAA59360.1), ended with double stop codon.
Brucella sequences were obtained synthetically. The
supernatants of transfected cells were used for inocula-
tion into 10-day-old CE (Lohmann Tierzucht GmbH,
Cuxhaven, Germany]) which was incubated at 34°С for
48 h. Vaccine batches were produced in CE after three
egg passages of viral constructs.
Genetic stability of the viral constructs
Five consecutive passages of four of the viral constructs
were accumulated in 10-day-old CE for genetic stability
testing. The allantoic cavity of the CE were infected using
10
−4 dilutions of inoculate. The genetic stability of the
viral constructs was confirmed by reverse transcription-
polymerase chain reaction (RT-PCR [49]) using NS
segment specific primers (sense 5′-ACTACTTCTAGA
GAAGACAAAGCAAAAGCAGGGTGACA-3′ and anti-
sense 5′-ACTACTCTGCAGATTAACCC TCACTAAAA
GTAGAAACAAG-3′). At passages 1, 3 and 5; the size of
the NS amplicons was compared to those of pHW plasmids
encoding the corresponding genes. The NS1-fusion protein
encoding genes of the viral constructs were sequenced at
p a s s a g e s1 ,3a n d5u s i n gt h eS a n g e rm e t h o dw i t ht h e
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Foster City, CA, USA) on a automatic 16-capillary sequen-
cer Genetic Analyser 3130 ×l (ABI).
Determination of the infectious titers of the viruses
The infectious titers of the viruses were determined
using 10-day old specific pathogen free (SPF) embryo-
nated chicken eggs by standard methods. Viral suspen-
sions (10
−1 – 10
−9 dilutions) were prepared in PBS
(pH 7.2) and the allantoic cavities of four CE were in-
fected with 0.2 ml of each dilution. The CE were incu-
bated at 34 ±0.5°C at a relative humidity of 60 ±5% for
48 h. After cooling by the drop method, the viral titers
were determined by the hemagglutination assay [50].
Viral titers were calculated using the method of Reed
and Muench [51], and expressed as Log10 EID50/ml.
Production of recombinant Brucella proteins
In order to obtain the recombinant L7/L12 and Omp16
proteins, the nucleotide sequences of the genes were
amplified from the genomic DNA of B. abortus 19 and
cloned into рЕТ (Novagen, Darmstadt, Germany) plas-
mid vectors, bacterial DNA was isolated using PrepMa-
nUltra kits (ABI). The primers used to amplify the genes
are listed in Table 3. Amplification was performed in
50 μl reactions containing 5 μl of 10× PCR buffer
(Qiagen, Hilden, Germany), 1 μl of 10 mM dNTPs
(NEB), 0.1 μl DNA, 1 μl of each primer (20 pmol/μl),
and 0.25 μl Taq DNA polymerase (2.5 U; Qiagen). Amp-
lification conditions were as follows: 94°C for 5 min;
30 cycles of 94°C for 1 min, 50°C for 1 min and 72°C for
2 min; and a final extension at 72°C for 7 min. The amp-
lified PCR products of the L7/L12 and Omp16 genes
were cloned into the рЕТ26 expression vector using the
XhoIa n dNdeI sites; the recombinant L7/L12 protein
contained a 6-HIS tag at the N- and C-termini, and the
recombinant Omp16 protein contained a 6-HIS tag at
the C-terminus. Next, E. coli strain T7 cells were trans-
formed with the recombinant expression plasmids, and
the recombinant proteins were purified using Ni-NTA
Agarose (MCLAB, South San Francisco, CA, USA) ac-
cording to the manufacturer’s instructions. The purified
proteins were identified by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot assays. The purified protein was stored
at – 70°C until use for ELISA or for in vitro stimulation
of splenocytes.
Western blot analysis of the expression of Brucella
proteins
Samples of allantoic fluid from uninfected CE and CE
infected with the viral constructs Flu-NS1-124-L7/L12-
H5N1, Flu-NS1-124-Omp16-H5N1, Flu-NS1-124-L7/L12-
H1N1, or Flu-NS1-124-Omp16-H1N1 were mixed with
RIPA lysis buffer (Sigma) in a 1:1 ratio, heated at 100°С for
5 min and centrifuged for 5 min at 13,000 rpm. Electro-
phoretic separation of the proteins was performed using
12% SDS-PAGE gels, and Coomassie G-250 dye or West-
ern blotting was used to visualize the proteins. For Western
blotting, the proteins were transferred to nitrocellulose
membranes. The membranes were blocked at room
temperature for 1 h in blocking buffer (150 mМ NaCl,
20 mM Tris–HCl, pH 7.5, containing 5% skimmed milk
powder). The blot was probed with rabbit anti L7/L12 or
Omp16 serum (Eurogentec S.A., Belgium) at a dilution
1:2000 in blocking buffer containing 0.1% Tween-20 for 2 h
at room temperature. Following 3 washes with TBST buffer
(150 mM NaCl, 20 mM Tris–HCl, pH 7.5, 0.1% Tween-
20), the blot was incubated for 1 – 2 h at room temperature
in G-alkaline phosphatase-conjugated goat-anti-rabbit IgG
antibody (Sigma) [8]. The membranes were washed three
times for 10 min each with TBST buffer, and then the
bands were visualized by the addition of BCIP/NBT sub-
strate (Sigma).
Laboratory animals and bioethics
This study used 150 female BALB/c mice aged 6-8-weeks-
old weighing 15 to 18 g (Charles River Laboratories,
Erkrath, Germany) and 55 female outbreed guinea pigs
weighing 300–350 g (National Center for Expertise of Drugs,
Medical Products and Equipment, Almaty, Kazakhstan).
T h el a b o r a t o r ym i c ew e r er a n d o m l yd i v i d e di n t o1 1g r o u p s :
nine experimental prime-boost groups (n=1 4 per g rou p)
immunized with the mono- or bivalent vaccine formula-
tions either i.n.( n=42), c.( n=4 2)ors.c.( n=42), one nega-
tive (PBS) control group (s.c., n=14), and one positive (B.
abortus 19) control group (s.c., n=10). The guinea pigs
were divided into 11 groups: nine experimental (n=5per
group) prime-boost groups immunized with the mono- or
bivalent vaccine formulations i.n.( n=15), c. (n=15) or s.c.
Table 3 Primers used for amplifying genes encoding Brucella proteins
Gene Primer Sequence
Omp16 (GenBank ID: AAA59360) omp16-f 5′-C G CATATGCGCCGTATCCAGTCGATTGCA -3′
omp16-r 5′-C G CTCGAGCCTTCCGGCCCCGTTGAGAA -3′
L7/L12 (GenBank ID: AAA19863.1) L7/L12-f 5′-CGCATATGGGAATTTCAAAAGCAAGTCT-3′
L7/L12-r 5′-CGCTCGAGGCGCGACAGCGTCACGGCCT-3′
Restriction sites are bold-faced, and start codons are shown in italics.
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one positive control group vaccinated with B. abortus 19
(s.c., n=5). The absence of outward signs of disease and
homogeneity of the groups by body weight (±20%) were
used as eligibility criteria for randomization. Experimental
and control groups of animals were kept in different rooms
during the entire experiment and all animals had free ac-
cess to water and standard rodent diet.
This study was carried out in compliance with national
and international laws and guidelines on laboratory ani-
mal handling. The protocol was approved by the Com-
mittee on the Ethics of Animal Experiments of the
Research Institute for Biological Safety Problems Science
Committee of the Ministry of Education and Science of
the Republic of Kazakhstan (Permit Number: 1012/405).
Immunization
After light anesthesia with methoxyflurane (Abbott La-
boratories, Abbot Park, Illinois, USA), the mice and
guinea pigs were i.n., c. or s.c. immunized twice with re-
combinant influenza A viruses of the Н5N1 subtype
(prime vaccination) and H1N1 subtype (booster vaccin-
ation) 28 days apart. A detailed immunization chart for
the animals is shown in Table 4. Guinea pigs and mice
from the positive control group were immunized once
s.c. with the attenuated strain B. abortus 19 at a dose of
2×1 0
9 CFU/animal and 10
5 CFU/animal, respectively.
Mice and guinea pigs of the negative control groups
were obtained s.c. 200 μl of PBS.
Evaluation of the safety of the viral constructs in mice
The safety of the viral constructs (or their degree of attenu-
ation) was evaluated in mice, and compared to the negative
(PBS) control group. For this purpose, the vaccinated mice
were observed daily. Safety was evaluated by monitoring
the animals’ survival rate, overall condition, behavior and
weight changes. Following necropsy morphological and
histological examinations were performed.
The animals’ survival rate, overall condition and be-
havior after immunization were evaluated over a 56-day
clinical observation period. The animals were weighed 0
and every day during 1–28 days after each vaccination.
Sampling
To evaluate the safety of the vaccine vectors, two ani-
mals from each experimental and negative control group
were euthanized by cervical dislocation 5 days after each
vaccination (n= 36). The heart, lungs, liver, kidneys and
spleen were excised for histological examination from
the euthanized mice after a post-mortem pathological-
anatomical examination. Twenty-eight days after the
prime (D 28) and boost (D 56) vaccinations, five mice
from each experimental, negative and positive control
group were euthanized and the spleens were collected
Table 4 Scheme of immunization of animals with recombinant influenza A viruses of the subtypes Н5N1 and H1N1
Species Viral construct Route of
administration
Number of
animals
Prime vaccination dose
(Н5N1), Log10 EID50/animal
Boost vaccination dose
(Н1N1), Log10 EID50/animal
Mice Monovalent Flu-NS1-124-L7/L12 i.n. 10 5.97 6.39
c. 10 5.58 6.08
s.c. 10 6.58 7.00
Monovalent Flu-NS1-124-Omp16 i.n. 10 5.51 5.64
c. 10 5.20 5.33
s.c. 10 6.12 6.25
Bivalent vaccine formulation Flu-NS1-124-L7/
L12+Flu-NS1-124-Omp16
i.n. 10 5.58+5.20 6.08+5.33
c. 10 5.27+4.89 5.69+4.99
s.c. 10 6.27+5.81 6.69+5.94
Guinea
pigs
Monovalent Flu-NS1-124-L7/L12 i.n. 5 6.28 6.70
c. 5 5.89 6.39
s.c. 5 6.58 7.00
Monovalent Flu-NS1-124-Omp16 i.n. 5 5.82 5.95
c. 5 5.51 5.64
s.c. 5 6.12 6.25
Bivalent vaccine formulation Flu-NS1-124-L7/
L12+Flu-NS1-124-Omp16
i.n. 5 5.97+5.51 6.39+5.64
c. 5 5.58+5.20 6.00+5.30
s.c. 5 6.27+5.81 6.69+5.94
The amounts of inoculate for the intranasal (i.n.), conjunctival (c.) or subcutaneous (s.c.) immunization routes were 50, 25, and 200 μl for mice, and 100, 50 and
200 μl for guinea pigs, respectively.
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using an ELISPOT. Blood samples were collected to
identify antibodies against the Brucella proteins L7/L12
and Omp16 using ELISA. Nasal swabs were collected
everyday during one week after each i.n. vaccination
with mono – and bivalent vaccine formulations and
eluted in tubes containing 1 ml of virus transport media
(sterile solution of calf infusion broth, fraction V of bo-
vine albumin, gentamicin sulphate, and Fungizone®) to
evaluate the virus shedding. After brief centrifugation
the nasal fluids were kept at - 70°C until titration in 10-
day-old CE.
Histological examination
The heart, lungs, liver, kidneys and spleen were collected
from the immunized mice for histological examinations.
Histological analysis was performed according to stand-
ard procedures using hematoxylin-eosin (Sintakon, St.
Petersburg, Russia) stained sections.
Isolation of lymphocyte cell populations and ELISPOT
assay
Spleens were mechanically dissociated into single cell
suspensions and filtered through cell strainers (BD
Falcon, BD Biosciences, San Jose, CA, USA). Red blood
cells were lysed using ACK solution (150 mM NH4Cl,
1 mM KHCO3, 0.1 mM Na2-EDTA, pH 7.3). Splenocytes
were cultured at 37°C in 5% CO2 in 96-well flat-
bottomed plates at an initial density of 4 × 10
5 cells/well
in RPMI-1640 medium supplemented with 2 mM L-glu-
tamine and 10% heat-inactivated FCS (Sigma), in the
presence of 0.8 μg of purified L7/L12 protein or Omp16
protein or heat-inactivated B. abortus 19 (10
6 CFU/well),
or no additives (unstimulated control). To determine the
numbers of cytokine-producing T cells, spleen cells were
stimulated in vitro for 48 h with L7/L12 protein or
Omp16 protein or heat-inactivated B. abortus 19, col-
lected, and IFN-γ was detected by an ELISPOT assay
utilizing Multiscreen-IP Millipore plates (Millipore, Bed-
ford, MA). All assays were performed in triplicate. The
spot number corresponding to the IFN-γ-producing cells
was calculated using an ELISPOT spot counter (Biorader
4000 PRO-X; BIOSYS GmbH, Germany). Cells incu-
bated in the absence of a stimulating antigen developed
<15 spots/4 × 10
5 cells.
ELISA
Ninety-six well microtiter plates (Nunc, Roskilde,
Denmark) were coated overnight with 2 μg/ml L7/L12
protein or Omp16 protein in PBS, blocked for 1 h using
PBS-1% ovalbumin (PBS-OVA; 200 μl/well), and washed
with PBS containing 0.05% Tween-20 (PBS/Tw). Serial
two-fold dilutions of the serum samples from immu-
nized mice (100 μl/well) diluted in PBS/OVA were added
to the plates and incubated for 1 h at room temperature.
After washing (4×), anti-rabbit IgG-HRP (100 μlo f
1:2000/well, Dako, Cambridge, UK) was added and the
plates were incubated for 1 h at room temperature. Fol-
lowing a washing step (4×), the plates were incubated
with the substrate O-phenylenediamine (OPD; 100 μl/
well; Norgen Biotek Corp., Ontario, Canada). The colori-
metric reaction was stopped with 2.5 M H2SO4 (100 μl/
well) and the optical density values were measured at
492 nm (reference wavelength, 620 nm). The cut-off
value for titer determination was calculated based on the
mean OD values of wells containing only buffer (blank)
+three standard deviations. Endpoint serum ELISA ti-
ters are presented as GMT ±standard error (SE).
Evaluation of protective efficacy
Twenty-eight days after the boost vaccination, guinea
pigs from the experimental (n= 45) and negative (PBS)
control groups were challenged s.c. with the virulent
strain B. abortus 544 at a dose of 5 × 10
2 CFU/animal.
Guinea pigs from the positive control group (n=5) were
challenged in a similar manner 56 days after a single
immunization with the vaccine strain B. abortus 19.
Thirty days post-challenge, all of the guinea pigs were
euthanized by CO2 asphyxiation and aseptically autop-
sied to remove the following organs: retropharyngeal,
lower cervical, right and left inguinal and paraaortic
lymph nodes, and liver, kidney, spleen, and bone mar-
row. The organs were plated onto TSA plates and the
plates were incubated at 37°С for 4 weeks. During this
time the growth of bacterial colonies was periodically
counted. An animal was considered to be infected if a
Brucella colony was detected from one or more organs.
The results of the bacteriological examination were eval-
uated as the number of animals from which no colonies
were isolated (effectiveness of vaccination) and by the
index of infection (the number of organs and lymph
nodes from which were isolated Brucella).
Determination of virulent Brucella from the spleens of
challenged animals was used as an additional indicator
of evaluation of protective efficacy. For this purpose, the
collected spleens were homogenized in 2 ml of 0.1%
Triton-PBS, and 100 μl aliquots of 10-fold serial dilu-
tions were plated in triplicate onto TSA plates, incu-
bated for 14 days at 37°C, and the number of CFU were
counted. Log10 units of protection were calculated as the
mean log10 numbers of CFU of the negative control
group (PBS) minus the mean log10 number of CFU of
the experimental group.
Statistical analysis
The difference in antibody titers to Brucella L7/L12 and
Omp16 proteins in ELISA and IFN-ץ producing cell in
ELISPOT assay between the groups of mice depending on
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was performed using one way ANOVA followed by
Tukey’s multiple comparisons test.
When defining a protective of mono-or bivalent vac-
cine formulations the difference between the experimen-
tal, positive and the negative control groups (PBS) in the
number (log10 CFU) allocated B. abortus 544 from the
spleen of guinea pigs and I.I. after challenge was deter-
mined using a one way ANOVA followed by Tukey’s
multiple comparisons test.
P values <0.05 were considered significant.
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